Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    B1931008
Show Display Options
Rank Status Study
1 Terminated A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Inotuzumab ozogamicin;   Drug: Rituximab;   Drug: rituximab + gemcitabine;   Drug: rituximab +bendamustine

Indicates status has not been verified in more than two years